Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Clinical trial NCT05311943 · UNKNOWN

Trial details

NCT number: NCT05311943
Sponsor: Shenzhen Second People's Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Olverembatinib Chronic Myeloid Leukemia, Chronic Phase Tyrosine Kinase Inhibitors

Start date: 2022-07-01
Primary completion: 2024-06-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.